228 related articles for article (PubMed ID: 34399812)
1. Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
Nilsson MP; Johnsson A; Scherman J
Radiat Oncol; 2021 Aug; 16(1):152. PubMed ID: 34399812
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
[TBL] [Abstract][Full Text] [Related]
3. Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
Lohynská R; Nýdlová A; Drbohlavová T; Mazaná E; Jirkovská M; Veselský T; Malinová B; Stankušová H
Klin Onkol; 2020; 33(4):288-294. PubMed ID: 32894958
[TBL] [Abstract][Full Text] [Related]
4. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
[TBL] [Abstract][Full Text] [Related]
5. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
Lee AY; Golden DW; Bazan JG; Kopec M; Pelizzari CA; Aggarwal S; Chang DT; Liauw SL
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):306-312. PubMed ID: 28068238
[TBL] [Abstract][Full Text] [Related]
6. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
[TBL] [Abstract][Full Text] [Related]
7. Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation.
Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Med Oncol; 2016 Dec; 33(12):137. PubMed ID: 27815805
[TBL] [Abstract][Full Text] [Related]
8. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
[TBL] [Abstract][Full Text] [Related]
9. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
[TBL] [Abstract][Full Text] [Related]
10. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197
[TBL] [Abstract][Full Text] [Related]
11. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric and Clinical Predictors for Acute and Late Gastrointestinal Toxicity Following Chemoradiotherapy of Locally Advanced Anal Cancer.
Nilsson MP; Gunnlaugsson A; Johnsson A; Scherman J
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):e35-e44. PubMed ID: 34598844
[TBL] [Abstract][Full Text] [Related]
13. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160
[TBL] [Abstract][Full Text] [Related]
15. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
Bazan JG; Luxton G; Mok EC; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):700-6. PubMed ID: 22414279
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
18. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
19. Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
El-Hadaad HA; Wahba HA; Roshdy S
J Gastrointest Cancer; 2015 Jun; 46(2):156-60. PubMed ID: 25810165
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
Thind G; Johal B; Follwell M; Kennecke HF
Radiat Oncol; 2014 May; 9():124. PubMed ID: 24885554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
